<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01635062</url>
  </required_header>
  <id_info>
    <org_study_id>2012P000905</org_study_id>
    <nct_id>NCT01635062</nct_id>
  </id_info>
  <brief_title>The VALIDATE-D Study</brief_title>
  <acronym>VALIDATE-D</acronym>
  <official_title>Evaluating Hormonal Mechanisms for Vitamin D Receptor Agonist Therapy in Diabetes: The VALIDATE-D Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate whether vitamin D receptor agonist therapy lowers
      renin-angiotensin system activity.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study aims to evaluate whether vitamin D receptor agonist therapy (calcitriol) in
      diabetes lowers renin-angiotensin system (RAS) activity in a manner similar to an ACE
      inhibitor. This is a physiology study, focused on evaluating hormonal changes in the
      circulating and tissue RAS when compared to placebo.

      Subjects with type 2 diabetes and obesity and normal kidney function will undergo evaluation
      of their circulating and renal-vascular RAS activity and urinary protein at baseline, after
      withdrawing interfering medications, while on a controlled electrolyte diet, and in
      controlled posture settings. They will then randomly receive a study medication (calcitriol
      or placebo) for 3 weeks followed by a re-assessment of their RAS parameters. The main
      outcomes that will be evaluated following calcitriol/placebo include measures of the
      circulating renin activity (primary), as well as measures of the renal-vascular RAS (renal
      plasma flow) and urine protein (secondary)

      The primary outcome is the change in the plasma renin activity when sodium restricted, before
      and after intervention. Secondary outcomes include the change in renal plasma flow and urine
      protein when sodium loaded, before and after intervention.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Change in Circulating RAS Activity After Calcitriol/Placebo Therapy</measure>
    <time_frame>baseline and 2 weeks following calcitriol/placebo therapy</time_frame>
    <description>The below results represent the change in Plasma Renin Activity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Renal Plasma Flow After Calcitriol/Placebo Therapy</measure>
    <time_frame>baseline and 3 weeks following calcitriol/placebo therapy</time_frame>
    <description>Subjects had their renal plasma flow assessed at baseline while sodium loaded, and again after 3 weeks of randomized therapy with either calcitriol (up to 0.75 mcg daily) or placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Urine Protein After Calcitriol/Placebo Therapy</measure>
    <time_frame>baseline and 3 weeks following calcitriol/placebo therapy</time_frame>
    <description>Subjects have their urine protein assessed at baseline while sodium loaded and again 3 weeks after randomized therapy with calcitriol or placebo.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Type 2 Diabetes</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>calcitriol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive calcitriol (titrated up to 0.75 mcg daily) for 3 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will receive placebo for 3 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcitriol</intervention_name>
    <description>Subjects will receive calcitriol (up to 0.75 mcg daily) for 3 weeks.</description>
    <arm_group_label>calcitriol</arm_group_label>
    <other_name>1,25-dihydroxyvitamin D3</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subjects will receive placebo for 3 weeks.</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Type-Two Diabetes (treated with diet alone, with oral hypoglycemic agents, or with a
             single injection of basal insulin daily)

          2. Normal blood pressure, or Mild (Stage 1) Hypertension that is either untreated, or
             adequately treated with a single anti-hypertensive drug.

          3. Age &gt;18 years and &lt;70 years

          4. Estimated GFR &gt; 60ml/min

          5. Normal laboratory values for: Complete blood count, sodium, potassium, glucose, liver
             enzymes, urinalysis

          6. Electrocardiogram without any signs of prior infarction, ventricular conduction
             abnormality, or supraventricular arrhythmia.

        Exclusion Criteria:

          1. Chronic Kidney Disease or eGFR&lt;60

          2. History of nephrolithiasis (kidney stones)

          3. Multiple (more than one) insulin injections daily (since insulin can alter the RAS)

          4. Poorly controlled type 2 diabetes (That may require more aggressive therapy) as
             defined by an HbA1c&gt;8.5%

          5. Type 1 diabetes

          6. Stage 2 or Stage 3 hypertension or the use of more than 1 antihypertensive drug

          7. Chronic inflammatory conditions (such as inflammatory bowel disease or arthritis) that
             are treated with prescribed doses of NSAIDs by a physician.

          8. The use of prescribed doses of potassium supplements.

          9. History of liver failure

         10. History of parathyroid or granulomatous disorders

         11. History of heart failure, cerebrovascular disease or coronary heart disease

         12. History of known microvascular complications of diabetes (including retinopathy,
             neuropathy, nephropathy)

         13. Illness requiring overnight hospitalization in the past 6 months

         14. Active tobacco or recreational drug use

         15. Pregnancy or current breast feeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anand Vaidya, MD, MMSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital, Harvard Medical School</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 2, 2012</study_first_submitted>
  <study_first_submitted_qc>July 3, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 6, 2012</study_first_posted>
  <results_first_submitted>January 6, 2017</results_first_submitted>
  <results_first_submitted_qc>February 28, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 11, 2017</results_first_posted>
  <last_update_submitted>February 28, 2017</last_update_submitted>
  <last_update_submitted_qc>February 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>Anand Vaidya</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine, Harvard Medical School</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcitriol</mesh_term>
    <mesh_term>Dihydroxycholecalciferols</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited from the local Boston community
A total of 41 participants were consented to participate. Subsequently, 13 were found ineligible, 5 withdrew participation, 3 were lost-to follow-up, and 2 were withdrawn for non-compliance with the washout. Therefore, 18 were randomized.</recruitment_details>
      <pre_assignment_details>An anti-hypertensive medication washout was conducted to minimize confounding of the renin-angiotensin system.
ACE inhibitors, angiotensin-receptor blockers, and mineralocorticoid receptor antagonists, beta blockers, diuretics, and calcium-channel blockers were withdrawn for 2 weeks to 2 months prior to randomization.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Calcitriol</title>
          <description>Subjects will receive calcitriol (titrated up to 0.75 mcg daily) for 3 weeks.
Subjects have their renin-angiotensin system, renal plasma flow, and urine protein assessed at baseline while sodium restricted and sodium loaded. They will then be randomized to receive calcitriol (up to 0.75 mcg daily) or placebo for 3 weeks, and repeat assessments again while sodium restricted and sodium loaded.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Subjects will receive placebo for 3 weeks.
Subjects have their renin-angiotensin system, renal plasma flow, and urine protein assessed at baseline while sodium restricted and sodium loaded. They will then be randomized to receive calcitriol (up to 0.75 mcg daily) or placebo for 3 weeks, and repeat assessments again while sodium restricted and sodium loaded.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Sodium Restriction Baseline Visit</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Sodium Loading Baseline Visit</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Post-randomization Sodium Restriction</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Post-Randomization Sodium Loaded</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Calcitriol</title>
          <description>Subjects will receive calcitriol (titrated up to 0.75 mcg daily) for 3 weeks.
Subjects have their renin-angiotensin system, renal plasma flow, and urine protein assessed at baseline while sodium restricted and sodium loaded. They will then be randomized to receive calcitriol (up to 0.75 mcg daily) or placebo for 3 weeks, and repeat assessments again while sodium restricted and sodium loaded.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Subjects will receive placebo for 3 weeks.
Subjects have their renin-angiotensin system, renal plasma flow, and urine protein assessed at baseline while sodium restricted and sodium loaded. They will then be randomized to receive calcitriol (up to 0.75 mcg daily) or placebo for 3 weeks, and repeat assessments again while sodium restricted and sodium loaded.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="18"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.0" spread="10.4"/>
                    <measurement group_id="B2" value="50.7" spread="5.0"/>
                    <measurement group_id="B3" value="50.8" spread="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Change in Circulating RAS Activity After Calcitriol/Placebo Therapy</title>
        <description>The below results represent the change in Plasma Renin Activity.</description>
        <time_frame>baseline and 2 weeks following calcitriol/placebo therapy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Calcitriol</title>
            <description>Subjects have their plasma renin activity assessed at baseline while sodium restricted, and again after 2 weeks of randomized therapy with calcitriol (up to 0.75 mcg daily) or placebo.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects have their plasma renin activity assessed at baseline while sodium restricted, and again after 2 weeks of randomized therapy with calcitriol (up to 0.75 mcg daily) or placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>The Change in Circulating RAS Activity After Calcitriol/Placebo Therapy</title>
          <description>The below results represent the change in Plasma Renin Activity.</description>
          <units>ng/mL/h</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="-1.3" upper_limit="0.3"/>
                    <measurement group_id="O2" value="-1.3" lower_limit="-3.6" upper_limit="-0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The hypothesis was that calcitriol therapy would lower plasma renin activity (PRA), when sodium restricted, when compared to placebo.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.69</p_value>
            <method>ANOVA</method>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>1.3</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Renal Plasma Flow After Calcitriol/Placebo Therapy</title>
        <description>Subjects had their renal plasma flow assessed at baseline while sodium loaded, and again after 3 weeks of randomized therapy with either calcitriol (up to 0.75 mcg daily) or placebo.</description>
        <time_frame>baseline and 3 weeks following calcitriol/placebo therapy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Calcitriol</title>
            <description>Subjects have their renal plasma flow assessed at baseline while sodium loaded. They will then be randomized to receive calcitriol (up to 0.75 mcg daily) or placebo for 3 weeks, and repeat renal plasma flow assessments again while sodium loaded.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects have their renal plasma flow assessed at baseline while sodium loaded. They will then be randomized to receive calcitriol (up to 0.75 mcg daily) or placebo for 3 weeks, and repeat renal plasma flow assessments again while sodium loaded.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Renal Plasma Flow After Calcitriol/Placebo Therapy</title>
          <description>Subjects had their renal plasma flow assessed at baseline while sodium loaded, and again after 3 weeks of randomized therapy with either calcitriol (up to 0.75 mcg daily) or placebo.</description>
          <units>mL/min/1.73m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.4" spread="180.5"/>
                    <measurement group_id="O2" value="-0.6" spread="142.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The hypothesis was that calcitriol therapy would raise renal plasma flow, when sodium loaded, when compared to placebo.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.89</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>15.8</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Urine Protein After Calcitriol/Placebo Therapy</title>
        <description>Subjects have their urine protein assessed at baseline while sodium loaded and again 3 weeks after randomized therapy with calcitriol or placebo.</description>
        <time_frame>baseline and 3 weeks following calcitriol/placebo therapy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Calcitriol</title>
            <description>Subjects have their urine protein assessed at baseline while sodium sodium loaded and again following 3 weeks of randomization to calcitriol (up to 0.75 mcg daily) or placebo.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects have their urine protein assessed at baseline while sodium sodium loaded and again following 3 weeks of randomization to calcitriol (up to 0.75 mcg daily) or placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Urine Protein After Calcitriol/Placebo Therapy</title>
          <description>Subjects have their urine protein assessed at baseline while sodium loaded and again 3 weeks after randomized therapy with calcitriol or placebo.</description>
          <units>mg/24h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.1" spread="95.7"/>
                    <measurement group_id="O2" value="8.1" spread="51.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The hypothesis was that calcitriol therapy would lower urine protein, when sodium loaded, when compared to placebo.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.80</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>13.0</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>They were collected for the duration of the study (~4 months)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Calcitriol</title>
          <description>Subjects will receive calcitriol (titrated up to 0.75 mcg daily) for 3 weeks.
Calcitriol: Subjects will receive calcitriol (up to 0.75 mcg daily) for 3 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Subjects will receive placebo for 3 weeks.
Placebo: Subjects will receive placebo for 3 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This was a small physiological study, not a treatment study or a typical Phase 1-4 study. The objective was to investigate the mechanistic link between vitamin D receptor agonist therapy and the renin-angiotensin system.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Anand Vaidya (Asst Professor of Medicine)</name_or_title>
      <organization>Brigham and Women's Hospital</organization>
      <phone>6175258285 ext 617</phone>
      <email>avaidya1@partners.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

